FLT3 and acute myeloid leukemia: Half of the AML samples were susceptible to the combination treatment with 1 μM idasanutlin and 50 nM cobimetinib including five FLT3wt and seven FLT3-ITD NK-AML samples with 30% to 60% cell viability after 24 h treatment (Table S1).